

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Genscript Biotech Corporation
金斯瑞生物科技股份有限公司 *
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 1548)

**RESIGNATION OF DIRECTORS AND
CHANGE IN COMPOSITION OF STRATEGY COMMITTEE**

This announcement is made by Genscript Biotech Corporation (the “**Company**”) pursuant to Rule 13.51(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

RESIGNATION OF DIRECTORS

The board (the “**Board**”) of directors (the “**Director(s)**”) of the Company wishes to announce that:

- (i) Ms. Wang Jiafen (“**Ms. Wang**”) had tendered resignation from her positions as a non-executive Director and a member of the strategy committee of the Company (the “**Strategy Committee**”) due to the attainment of statutory retirement age, with effect from 5 July 2024; and
- (ii) Dr. Wang Xuehai (“**Dr. Wang**”) had tendered resignation from his position as an independent non-executive Director due to his intention to devote more time to other business commitments, with effect from 5 July 2024.

Each of Ms. Wang and Dr. Wang has confirmed that she/he has no disagreement with the Board and there is no other matter in relation to their respective resignation that needs to be brought to the attention of the shareholders of the Company.

The Board would like to express its gratitude to Ms. Wang and Dr. Wang for their outstanding contributions and wise counsel during their tenures and offers its best wishes to them.

CHANGE IN COMPOSITION OF STRATEGY COMMITTEE

The Board further announces that, with effect from 5 July 2024, Ms. Wang ceased to be a member of the Strategy Committee and Dr. Shi Chenyang, an independent non-executive Director of the Company, has been appointed as a new member of the Strategy Committee.

Following the above changes, the Strategy Committee comprises four members, namely Dr. Zhang Fangliang (*Chairman*), Mr. Dai Zumian, Mr. Pan Jiuan and Dr. Shi Chenyang.

By order of the Board
GenScript Biotech Corporation
MENG Jiange
Chairman and Executive Director

Hong Kong, 5 July 2024

As at the date of this announcement, the executive Directors are Dr. Zhang Fangliang, Mr. Meng Jiange, Ms. Wang Ye and Dr. Zhu Li; the non-executive Director is Dr. Wang Luquan; and the independent non-executive Directors are Mr. Dai Zumian, Mr. Pan Jiuan, Mr. Cheung Yiu Leung Andy and Dr. Shi Chenyang.

** For identification purposes only*